Affinity Asset Advisors LLC Invests $2.87 Million in CG Oncology, Inc. (NASDAQ:CGON)

Affinity Asset Advisors LLC acquired a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 100,000 shares of the company's stock, valued at approximately $2,868,000. Affinity Asset Advisors LLC owned approximately 0.13% of CG Oncology as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CG Oncology in the 4th quarter worth about $68,000. KLP Kapitalforvaltning AS purchased a new position in shares of CG Oncology during the fourth quarter valued at about $100,000. Federated Hermes Inc. purchased a new stake in CG Oncology during the fourth quarter valued at $172,000. Meeder Asset Management Inc. bought a new position in shares of CG Oncology in the 4th quarter valued at about $189,000. Finally, NEOS Investment Management LLC raised its position in CG Oncology by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after purchasing an additional 817 shares during the period. Hedge funds and other institutional investors own 26.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Scotiabank started coverage on CG Oncology in a research report on Wednesday. They set a "sector perform" rating and a $23.00 target price for the company. Morgan Stanley reiterated an "overweight" rating and set a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research report on Monday, March 31st. Finally, TD Cowen started coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of "Buy" and an average target price of $59.33.

CG Oncology Price Performance

NASDAQ:CGON traded up $0.42 during midday trading on Friday, hitting $20.64. The company's stock had a trading volume of 1,109,544 shares, compared to its average volume of 721,402. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $46.99. The firm's 50 day moving average is $24.32 and its 200-day moving average is $29.76. The firm has a market cap of $1.57 billion, a P/E ratio of -14.54 and a beta of 1.24.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The company had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.11 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. As a group, analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.